Oral News and Research

RSS

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

J&JPRD submits New Drug Application to FDA for rivaroxaban

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

6 Jan 2011

Columbia research team identifies bacteria may play a key role in atherosclerosis

Dr. Emil Kozarov and a team of researchers at the Columbia University College of Dental Medicine have identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" - the number one cause of death in the United States.

6 Jan 2011

Nicotine replacement therapies to quit smoking

Although smoking is an expensive habit, let's face it, nicotine replacement therapies (NRT) to help you quit smoking can seem like expensive purchases as well.

6 Jan 2011

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease.

6 Jan 2011

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson. Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty pharmaceutical company focused on dental and oral health care.

6 Jan 2011

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Teva acquires Théramex

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.

5 Jan 2011

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

According to the American Academy of Pediatrics, sweetened drinks are the primary source of added sugar in the daily diet of children. Each 12-ounce serving of a carbonated, sweetened soft drink contains the equivalent of 10 teaspoons of sugar and 150 calories. A child who consumes one can of regular soda needs to walk 45 minutes just to burn it off.

5 Jan 2011

Star Scientific plans to submit new, moist-snuff product for FDA evaluation

Star Scientific Inc.'s plan to submit a new, moist-snuff product for evaluation by the Food and Drug Administration as a "modified risk" tobacco product shows the vital importance of the new law giving the FDA the authority to regulate tobacco products and any health claims used to market them.

5 Jan 2011

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Atherosclerosis is the leading cause of death in the developed world. While a number of risk factors for atherosclerosis have been defined, scientists continue to study other possible risk factors for this disease. Recent epidemiological and experimental studies link infectious agents with the development of inflammatory atherosclerosis. A hallmark of chronic infection with the oral pathogen Porphyromonas gingivalis is the induction of a chronic inflammatory response.

5 Jan 2011

CIGNA announces introduction of Dental Network Savings Program

CIGNA today announced the introduction of the Dental Network Savings Program, designed to provide Dental PPO and Dental Indemnity clients and customers additional savings opportunities when receiving covered dental plan services from a participating program dentist.

5 Jan 2011

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.

5 Jan 2011

Alpha Omega International Dental Fraternity honors Henry Schein Chairman and CEO

Alpha Omega International Dental Fraternity honored Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, Inc., the largest distributor of health care products and services to office-based practitioners, at the Organization's 2010 Annual Sunny Days Convention.

4 Jan 2011

Researchers report estrogen may increase movement of precancerous cells in oral cavity

Head and neck cancer is the sixth most common type of cancer and is on the rise in some demographic groups, including young women without any known risk factors. Now, researchers at Fox Chase Cancer Center report that estrogen may increase the movement of precancerous cells in the mouth and thus promote the spread of the disease within the oral cavity.

4 Jan 2011

Risk-adjusted TTR appears to improve anticoagulation control

Researchers from Boston University School of Medicine and the Bedford VA Medical Center believe that risk-adjusted percent time in therapeutic range should be used as part of an effort to improve anticoagulation control and thus improve patient outcomes.

4 Jan 2011

FDA approves 200 mg formulation of INTELENCE for HIV-1

The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.

3 Jan 2011

Oral News and Research

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

J&JPRD submits New Drug Application to FDA for rivaroxaban

Columbia research team identifies bacteria may play a key role in atherosclerosis

Nicotine replacement therapies to quit smoking

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

Teva acquires Théramex

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

Star Scientific plans to submit new, moist-snuff product for FDA evaluation

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

CIGNA announces introduction of Dental Network Savings Program

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Alpha Omega International Dental Fraternity honors Henry Schein Chairman and CEO

Researchers report estrogen may increase movement of precancerous cells in oral cavity

Risk-adjusted TTR appears to improve anticoagulation control

FDA approves 200 mg formulation of INTELENCE for HIV-1

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News